Author

G. A. Amos Burke

Cambridge University Hospitals NHS Foundation TrustORCID 0000-0003-2671-9972Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Adrienne Margaret FlanaganiD· 1 shared Andrew R. J. LawsoniD· 1 shared Anna Tollit· 1 shared Bengt HallbergiD· 1 shared Charlotte Barrett· 1 shared Christopher Steel· 1 shared Darren R. HargraveiD· 1 shared Emily R. JamesiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrienne Margaret FlanaganORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyNature GeneticsPeer-reviewedFeb 25, 2025

Cancer-independent, second somatic NF1 mutation of normal tissues in neurofibromatosis type 1

Thomas R. W. Oliver, Andrew R. J. Lawson, Henry Lee-Six…·Sam Behjati

The paper identifies second somatic NF1 mutations in normal tissues of neurofibromatosis type 1 patients through whole genome and exome sequencing, showing positive selection of truncating mutations in these tissues.

14 citationstop 2%

humanwhole-exome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 5, 2024

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma

Perla Pucci, Charlotte Barrett, Ricky M. Trigg…·Suzanne Dawn Turner

This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.

1 citation

humangenetic perturbation / CRISPR

𝕏 PostBluesky